Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid Birch 5000 in Allergic Rhinitis
NCT01694836Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Sep 2012
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines, Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of depigoid birch in allergic rhinitis (AR), Rhinoconjunctivitis (RC), sponsored by LETI Pharma. Started Sep 2012; status: completed.
02
Drugs
depigoid birch
03
Conditions
allergic rhinitis (AR)Rhinoconjunctivitis (RC)
Beyond the preview
Go deeper on NCT01694836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01694836.